TKNO stock forecast, quote, news & analysis
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics... Show more
Why Alpha Teknova (TKNO) Stock Is Down 36% in the Last 30 Days
Key Takeaways
- Alpha Teknova (TKNO) shares fell roughly 36% over the last 30 days, from about $8.34 to about $5.38, driven primarily by a dilutive common stock offering announced in mid-October.
- The underwritten offering priced 8 million shares at $5.00 each, well below the prior close of $7.39, triggering a single-session decline of roughly 27%.
- Preliminary third-quarter results were positive on the surface — revenue of $12.5 million to $12.7 million, up 19% to 21% year over year — but were overshadowed by shareholder dilution concerns.
- Over the trailing quarter, the stock rallied from the low-$5 range to a peak above $9 before giving back most of those gains.
- Cautious sentiment toward unprofitable small-cap life sciences companies amplified the post-offering selloff.
Alpha Teknova (TKNO) Company Overview and Market Position
Alpha Teknova, Inc. is a Hollister, California-based life sciences manufacturer that produces critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Founded in 1996, the company supplies pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements, and molecular biology reagents for sample manipulation, resuspension, and purification.
The business is organized around two product categories: Lab Essentials, which comprises catalog products for biological research and drug discovery, and Clinical Solutions, which provides custom, GMP-grade products supporting protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. Its customers span pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. Investors follow the stock for its exposure to the broader bioprocessing and life sciences tools market and its improving margin trajectory.
Alpha Teknova (TKNO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TKNO shares declined approximately 35.6%, falling from a closing price of $8.34 on September 21 to roughly $5.38 as of late October. Most of that decline was concentrated in a single session following the announcement and pricing of a $40 million equity offering.
The trailing three-month picture tells a different story. The stock entered mid-July near $5.34 and climbed steadily through August and September, reaching a peak near $9.30 in late September — not far from its 52-week high of $9.48. That advance was followed by a steady October pullback and, ultimately, the sharp offering-driven drop. Measured from roughly three months ago to the present, the shares are essentially flat, but the round trip masks considerable volatility.
What Drove TKNO Stock Price in the Last 30 Days
The dominant catalyst behind the 30-day decline was a dilutive capital raise. In mid-October, Alpha Teknova announced an underwritten public offering of its common stock, which it subsequently priced at 8 million shares at $5.00 per share for gross proceeds of $40 million. The offering price represented a discount of roughly 32% to the prior close of $7.39, and the new shares equated to roughly 15% of the company's approximately 53.7 million shares outstanding. Underwriters also received a 30-day option to purchase up to an additional 1.2 million shares. TD Cowen and William Blair acted as joint book-running managers.
The dilution drove shares down sharply — approximately 22% in after-hours trading immediately following the announcement, with additional selling into the following session. The company said proceeds would be used for general corporate purposes, including the potential repayment of outstanding debt obligations, and potentially for investments in complementary businesses or technologies.
Alongside the offering, Teknova disclosed preliminary, unaudited third-quarter results. The company estimated revenue between $12.5 million and $12.7 million, above the analyst consensus of roughly $11.7 million and up 19% to 21% from the prior-year period. Gross margin was estimated between 36% and 38%, while adjusted EBITDA was estimated at a loss of $1.2 million to $1.0 million, an improvement of at least 25% year over year. Cash and short-term investments stood at approximately $16.6 million as of September 30. Despite the constructive operating figures, the equity issuance dominated investor reaction.
What Drove TKNO Stock Performance Over the Last Quarter
The broader quarterly trend was shaped by improving fundamentals and a sharp rally that later unwound. In early August, following the release of second-quarter 2026 results, shares jumped from about $5.61 to $6.53 in a single session, reflecting investor enthusiasm around revenue growth and margin expansion. The advance continued through September as the stock approached $9.30, lifting its year-to-date gain to roughly 94% at one point.
That momentum faded in October as the shares drifted lower from their late-September peak, and the subsequent equity offering accelerated the reversal. The sequence illustrates how a high-valuation, still-unprofitable small-cap can rally rapidly on improving fundamentals and then give back gains quickly when financing dilution re-enters the picture.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's AI-driven trading bots. While Tickeron hosts hundreds of AI robots that trade thousands of tickers, only the top-performing and most relevant bots are featured in this section. These robots vary in strategy, timeframe, and performance metrics, giving traders a way to explore automated approaches suited to different market conditions and risk preferences. For investors monitoring stocks like TKNO, the page provides a useful starting point for evaluating data-driven trading tools. Consider reviewing the Trending AI Robots section to see which strategies are currently resonating across the market.
TKNO Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape TKNO's share price in the near term. The completion and closing of the common stock offering — including whether underwriters exercise their over-allotment option — will clarify the full extent of dilution and the company's resulting cash position. Investors will also watch for the release of full third-quarter 2026 results, which the company has indicated are subject to the completion of closing procedures and quarterly review.
Beyond the offering, key areas to monitor include progress against the company's 2026 revenue guidance of $42 million to $44 million, gross-margin expansion, and its path toward reducing adjusted EBITDA losses and cash burn. Debt repayment using offering proceeds could also affect the balance sheet. Analysts, who as of the offering announcement largely rated the stock Buy or Strong Buy with a median price target around $9.50, will likely reassess estimates following the new share count. Broader sentiment toward small-cap and unprofitable life sciences names, as well as macroeconomic conditions, will continue to influence trading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TKNO's RSI Indicator climbs out of oversold territory
The RSI Oscillator for TKNO moved out of oversold territory on October 22, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on TKNO as a result. In 69 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TKNO just turned positive on October 29, 2026. Looking at past instances where TKNO's MACD turned positive, the stock continued to rise in 43 of 46 cases over the following month. The odds of a continued upward trend are 90%.
TKNO moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TKNO crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +11.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where TKNO advanced for three days, in 226 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
TKNO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TKNO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TKNO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.698) is normal, around the industry mean (6.379). P/E Ratio (-25.194) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (8.718) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TKNO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TKNO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric